Santen EMEA and NTC are delighted to announce that the results of their phase III clinical study, LEADER7, have been published in Eye. The study demonstrated for the ...

ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today ...

Optifye Therapeutics has struck a deal with DelSiTech for controlled-release dexamethasone eye drops. The exclusive license agreement covers a candidate that uses DelSiTech Silica Matrix technology to ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Using Dextenza as a postoperative steroid treatment after cataract surgery saved practices about ...

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PARK CITY, Utah — Stage one of the phase 3 DIAMOND trial ...